ADPT

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Retrieved on: 
Thursday, February 22, 2024

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.

Key Points: 
  • SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.
  • Adaptive Biotechnologies’ management is scheduled to present on Monday, March 4th at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com .

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 14, 2024

clonoSEQ test volume increased 49% to 15,680 tests delivered in the fourth quarter of 2023, compared to the fourth quarter 2022 and ended the year with 56,496 tests delivered, up 53% versus 2022.

Key Points: 
  • clonoSEQ test volume increased 49% to 15,680 tests delivered in the fourth quarter of 2023, compared to the fourth quarter 2022 and ended the year with 56,496 tests delivered, up 53% versus 2022.
  • Revenue was $45.8 million for the quarter ended December 31, 2023, representing a 17% decrease from the fourth quarter in the prior year.
  • Interest and other income, net was $4.6 million for the fourth quarter of 2023, compared to $2.6 million in the fourth quarter of the prior year.
  • Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2023 financial results after market close on Wednesday, February 14, 2024 at 4:30 PM Eastern Time.

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Retrieved on: 
Monday, January 29, 2024

SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 14, 2024.

Key Points: 
  • SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 14, 2024.
  • Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com .
  • The webcast will be archived and available for replay within 24 hours after the event.

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 27, 2023

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Key Points: 
  • SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
  • Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 9th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com .

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Retrieved on: 
Saturday, December 9, 2023

The data are being presented in more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California.

Key Points: 
  • The data are being presented in more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California.
  • “The already-substantial body of evidence supporting clonoSEQ’s prognostic value and clinical actionability is expanding in several important ways at ASH this year,” said Susan Bobulsky, Senior Vice President, Diagnostics, Adaptive Biotechnologies.
  • At this timepoint, MRD status from both PB and BM were similarly prognostic of patients’ progression-free survival (PFS).
  • 88% (15/17) of patients that were MRD negative at day 28 remained MRD negative at 6 months.

Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2023.
  • clonoSEQ test volume in the third quarter 2023 grew 56% to 15,072 tests delivered versus the third quarter of prior year.
  • Revenue was $37.9 million for the quarter ended September 30, 2023, representing a 21% decrease from the third quarter in the prior year.
  • Adaptive Biotechnologies will host a conference call to discuss its third quarter 2023 financial results after market close on Thursday, November 9, 2023 at 4:30 PM Eastern Time.

Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline

Retrieved on: 
Tuesday, November 7, 2023

“Adaptive is pleased to partner with BeiGene to support the clinical development and potential regulatory approval of their investigational therapies in lymphoid malignancies,” said Mary Pat Lancelotta, Senior Vice President, BioPharma at Adaptive Biotechnologies.

Key Points: 
  • “Adaptive is pleased to partner with BeiGene to support the clinical development and potential regulatory approval of their investigational therapies in lymphoid malignancies,” said Mary Pat Lancelotta, Senior Vice President, BioPharma at Adaptive Biotechnologies.
  • It has been included in global, label-enabling studies for a multitude of therapies approved over the past several years and is also now widely adopted in the clinic.
  • This multi-year agreement will cover existing and future programs and adds to Adaptive’s growing list of translational collaborations with biopharmaceutical companies.
  • Adaptive will receive an upfront payment and will be eligible to receive future milestone payments upon achievement of specific regulatory milestones in certain geographies.

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023

Retrieved on: 
Thursday, November 2, 2023

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter of 2023 after market close on Thursday, November 9, 2023.

Key Points: 
  • SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter of 2023 after market close on Thursday, November 9, 2023.
  • Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com .
  • The webcast will be archived and available for replay within 24 hours after the event.

Adaptive Announces Launch of Epic Integration for clonoSEQ®

Retrieved on: 
Wednesday, September 13, 2023

This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care.

Key Points: 
  • This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care.
  • clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT).
  • Integration with Epic EHR provides convenient access to clonoSEQ MRD results along with discrete data directly in patient records, enabling faster, more efficient decision-making for oncologists and equipping patients with real-time insights into their disease status.
  • Practices that wish to access clonoSEQ MRD testing directly via Epic should contact their Adaptive account representative or Adaptive’s Account Operations team at [email protected].

Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Wednesday, August 30, 2023

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York

Key Points: 
  • SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York
    Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Wednesday, September 13th at 1:35 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com .